Market Overview:
The global tenofovir disoproxil fumarate and its combination drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of HIV/AIDS, rising demand for novel antiretroviral therapies, and growing number of clinical trials for new drug combinations. Based on type, the global tenofovir disoproxil fumarate and its combination drugs market is segmented into tenofovir disoproxil fumarate, efavirenz/tenofovir disoproxil fumarate/emtricitabine, rilpivirine/tenofovir disoproxil fumarate/emtricitabine, elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine, tenofovir disoproxil fumarate/emtricitabine lamivudine-containing regimens (3TC), efavirenz-lamivudine-containing regimens (3TC), elvitegravIR-cobicistat containing regimen (EVG)/lamivudinE containing regimen (3TC)/tenoFOVIR dIsoPproxIl FumatARe.
Product Definition:
Tenofovir Disoproxil Fumarate (TDF) is a nucleotide reverse transcriptase inhibitor (NRTI) that is used in combination with other antiretroviral agents for the treatment of HIV infection. TDF inhibits the replication of HIV by interfering with the viral enzyme reverse transcriptase. It is available as a tablet and oral suspension. The most common side effects associated with TDF therapy are headache, diarrhea, and nausea. Other potential side effects include renal impairment, lactic acidosis, and mitochondrial toxicity.
Tenofovir Disoproxil Fumarate:
It is a nucleotide analog that acts as an antiviral agent. It reduces the viral load and aids in recovery from SARS-CoV-2 infection by decreasing the amount of virus released into the blood and by inhibiting coronavirus replication.
The drug was approved for treatment of HIV-1 infected patients in France, Spain, Germany, Belgium, Luxembourg.
Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine:
Efavirenz/tenofovir disoproxil fumarate/emtricitabine is a drug combination used for the treatment of HIV-1 infection. It is part of a class of drugs known as reverse transcriptase inhibitors.
Application Insights:
The other application segment includes research studies and domestic applications. Other applications of tenofovir disoproxil fumarate include the treatment of HIV infection in children, adolescents, and adults. The drug is also used for the treatment of Hepatitis C as well as various other diseases such as tuberculosis (TB).
Clinic-based studies have shown that tenofovir disoproxil fumarate is more effective than lamivudine in preventing HIV transmission through heterosexual sex by reducing viral load to below detection limit levels in blood samples. In addition, it has been proven to be highly effective against drug-resistant strains of HIV. These factors are anticipated to increase demand from both domestic and international markets over the forecast period.
Regional Analysis:
North America dominated the global tenofovir disoproxil fumarate and its combination drugs market in 2017. This is attributed to the presence of key players, such as Gilead Sciences, Inc.; AbbVie Inc.; Merck & Co., Inc.; and F. Hoffman La-Roche Ltd., in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period due to factors such as growing population, awareness about HIV infection prevention among high-risk groups (men who have sex with men), rising disposable income leading towards increased utilization of these drugs for treatment and prevention of disease progression rather than just maintaining a healthy lifestyle modification approach taken by people living in developed countries like North America & Europe thus boosting market growth during the forecast period.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global prevalence of HIV is currently around 34 million, and it is estimated that around 2.5 million people are newly infected with the virus every year. This number is only going to increase in the coming years, as a result of which the demand for Tenofovir Disoproxil Fumarate and its combination drugs will also go up significantly.
- Rising awareness about HIV prevention: There has been a significant rise in awareness about HIV prevention in recent years, thanks to various campaigns by governments and NGOs alike. This has led to an increase in the use of Tenofovir Disoproxil Fumarate and its combination drugs for pre-exposure prophylaxis (PrEP).
- Growing demand for long-term antiretroviral therapy: The global market for long-term antiretroviral therapy is expected to grow at a CAGR of over 9% during the period 2017-2025. This will create significant opportunities for Tenofovir Disoproxil Fumarate and its combination drugs manufacturers worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Research Report
By Type
Tenofovir Disoproxil Fumarate, Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine, Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine, Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine, Tenofovir Disoproxil Fumarate/Emtricitabine, Lamivudine/Tenofovir Disoproxil Fumarate, Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Alkem Laboratories, Anhui Biochem Pharmaceutical, Beijing SL Pharmaceutical, Bristol-Myers Squibb, Chengdu Brilliant Pharmaceutical, CHIA TAI TIANQING (CTTQ) Pharmaceutical, Cipla, Cisen Pharmaceutical, Dr Reddy's Laboratories, Emcure Pharmaceuticals, Fujian Cosunter Pharmaceutical, Gilead Sciences, GlaxoSmithKline, Haisco Pharmaceutical, Hetero Drugs, Janssen Pharmaceutica (Johnson & Johnson), Mylan Pharmaceuticals, Natco Pharma, Qilu Pharmaceutical, Sun Pharmaceutical Industries, Teva, Torrent Pharmaceuticals, United Laboratories, Veritaz Healthcare, Wockhardt Ltd, Zydus Cadila
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
153
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Report Segments:
The global Tenofovir Disoproxil Fumarate and Its Combination Drugs market is segmented on the basis of:
Types
Tenofovir Disoproxil Fumarate, Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine, Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine, Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine, Tenofovir Disoproxil Fumarate/Emtricitabine, Lamivudine/Tenofovir Disoproxil Fumarate, Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alkem Laboratories
- Anhui Biochem Pharmaceutical
- Beijing SL Pharmaceutical
- Bristol-Myers Squibb
- Chengdu Brilliant Pharmaceutical
- CHIA TAI TIANQING (CTTQ) Pharmaceutical
- Cipla
- Cisen Pharmaceutical
- Dr Reddy's Laboratories
- Emcure Pharmaceuticals
- Fujian Cosunter Pharmaceutical
- Gilead Sciences
- GlaxoSmithKline
- Haisco Pharmaceutical
- Hetero Drugs
- Janssen Pharmaceutica (Johnson & Johnson)
- Mylan Pharmaceuticals
- Natco Pharma
- Qilu Pharmaceutical
- Sun Pharmaceutical Industries
- Teva
- Torrent Pharmaceuticals
- United Laboratories
- Veritaz Healthcare
- Wockhardt Ltd
- Zydus Cadila
Highlights of The Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tenofovir Disoproxil Fumarate
- Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
- Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
- Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
- Tenofovir Disoproxil Fumarate/Emtricitabine
- Lamivudine/Tenofovir Disoproxil Fumarate
- Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tenofovir Disoproxil Fumarate and Its Combination Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI). It is used to treat HIV infection. Tenofovir disoproxil fumarate and its combination drugs are also used to prevent the spread of HIV in people who are already infected with the virus.
Some of the major players in the tenofovir disoproxil fumarate and its combination drugs market are Alkem Laboratories, Anhui Biochem Pharmaceutical, Beijing SL Pharmaceutical, Bristol-Myers Squibb, Chengdu Brilliant Pharmaceutical, CHIA TAI TIANQING (CTTQ) Pharmaceutical, Cipla, Cisen Pharmaceutical, Dr Reddy's Laboratories, Emcure Pharmaceuticals, Fujian Cosunter Pharmaceutical, Gilead Sciences, GlaxoSmithKline, Haisco Pharmaceutical, Hetero Drugs, Janssen Pharmaceutica (Johnson & Johnson), Mylan Pharmaceuticals, Natco Pharma, Qilu Pharmaceutical, Sun Pharmaceutical Industries, Teva, Torrent Pharmaceuticals, United Laboratories, Veritaz Healthcare, Wockhardt Ltd, Zydus Cadila.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tenofovir Disoproxil Fumarate and Its Combination Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size & Forecast, 2018-2028
4.5.1 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size and Y-o-Y Growth
4.5.2 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Absolute $ Opportunity
Chapter 5 Global Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Type
5.2.1 Tenofovir Disoproxil Fumarate
5.2.2 Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
5.2.3 Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
5.2.4 Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
5.2.5 Tenofovir Disoproxil Fumarate/Emtricitabine
5.2.6 Lamivudine/Tenofovir Disoproxil Fumarate
5.2.7 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tenofovir Disoproxil Fumarate and Its Combination Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Type
9.6.1 Tenofovir Disoproxil Fumarate
9.6.2 Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
9.6.3 Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
9.6.4 Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
9.6.5 Tenofovir Disoproxil Fumarate/Emtricitabine
9.6.6 Lamivudine/Tenofovir Disoproxil Fumarate
9.6.7 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tenofovir Disoproxil Fumarate and Its Combination Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Type
10.6.1 Tenofovir Disoproxil Fumarate
10.6.2 Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
10.6.3 Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
10.6.4 Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
10.6.5 Tenofovir Disoproxil Fumarate/Emtricitabine
10.6.6 Lamivudine/Tenofovir Disoproxil Fumarate
10.6.7 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tenofovir Disoproxil Fumarate and Its Combination Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Type
11.6.1 Tenofovir Disoproxil Fumarate
11.6.2 Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
11.6.3 Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
11.6.4 Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
11.6.5 Tenofovir Disoproxil Fumarate/Emtricitabine
11.6.6 Lamivudine/Tenofovir Disoproxil Fumarate
11.6.7 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tenofovir Disoproxil Fumarate and Its Combination Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Type
12.6.1 Tenofovir Disoproxil Fumarate
12.6.2 Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
12.6.3 Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
12.6.4 Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
12.6.5 Tenofovir Disoproxil Fumarate/Emtricitabine
12.6.6 Lamivudine/Tenofovir Disoproxil Fumarate
12.6.7 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tenofovir Disoproxil Fumarate and Its Combination Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Type
13.6.1 Tenofovir Disoproxil Fumarate
13.6.2 Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine
13.6.3 Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine
13.6.4 Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine
13.6.5 Tenofovir Disoproxil Fumarate/Emtricitabine
13.6.6 Lamivudine/Tenofovir Disoproxil Fumarate
13.6.7 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tenofovir Disoproxil Fumarate and Its Combination Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tenofovir Disoproxil Fumarate and Its Combination Drugs Market: Competitive Dashboard
14.2 Global Tenofovir Disoproxil Fumarate and Its Combination Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alkem Laboratories
14.3.2 Anhui Biochem Pharmaceutical
14.3.3 Beijing SL Pharmaceutical
14.3.4 Bristol-Myers Squibb
14.3.5 Chengdu Brilliant Pharmaceutical
14.3.6 CHIA TAI TIANQING (CTTQ) Pharmaceutical
14.3.7 Cipla
14.3.8 Cisen Pharmaceutical
14.3.9 Dr Reddy's Laboratories
14.3.10 Emcure Pharmaceuticals
14.3.11 Fujian Cosunter Pharmaceutical
14.3.12 Gilead Sciences
14.3.13 GlaxoSmithKline
14.3.14 Haisco Pharmaceutical
14.3.15 Hetero Drugs
14.3.16 Janssen Pharmaceutica (Johnson & Johnson)
14.3.17 Mylan Pharmaceuticals
14.3.18 Natco Pharma
14.3.19 Qilu Pharmaceutical
14.3.20 Sun Pharmaceutical Industries
14.3.21 Teva
14.3.22 Torrent Pharmaceuticals
14.3.23 United Laboratories
14.3.24 Veritaz Healthcare
14.3.25 Wockhardt Ltd
14.3.26 Zydus Cadila
